First Tracks Raises $200M at $32.75/Share, a 6% Discount to Last Close
TRAX has more than doubled off its 52-week low of $14.72.
Summary
First Tracks is selling 6.1 million shares at $32.75 to a group of institutional investors, raising roughly $200M gross — about 16% of the company's market value. The price is a modest 6% discount to the $34.98 close, and the buyer list includes new and existing names like Affinity, First Light, Sirenia, TCGX and Vestal Point, which suggests real demand rather than a distressed raise. The cash is earmarked for ANB033, the CD122 antagonist that just posted positive Phase 1b celiac data on October 12 — this funding directly extends that program's runway. Dilution is material but the raise is well-covered and priced close to market, so the read is neutral-to-slightly-positive rather than a red flag. Closing is expected October 19, subject to customary conditions.
Updates
· SEC 8-K — The private placement covers 6,106,870 shares at $32.75, with closing expected October 19 and a resale registration statement due within 30 days of closing.
At the time of this announcement, TRAX was trading at $34.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $14.72 to $49.91. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.